Experimental cell therapy for advanced gynecological cancers shows early safety data
NCT ID NCT06191900
First seen Apr 29, 2026 · Last updated May 13, 2026 · Updated 3 times
Summary
This early study tested a new treatment called GT201 for people with advanced gynecological tumors, including cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was very small with only 4 participants and was stopped early. The main goal was to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.